A multicentre phase-II trial of thalidomide in relapsed/refractory multiple myeloma (MM) reveals a dominant adverse prognostic impact of advanced age.

被引：0
|
作者：
Prince, M
Mileshkin, L
Biagi, JJ
Smith, JG
Mitchell, P
Underhill, C
Grigg, A
Bell, R
McKendrick, J
Briggs, P
Seymour, JF
Simmons, PJ
Zeldis, JB
机构：
[1] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
[2] Austin Repatriat Med Ctr, Heidelberg, Vic, Australia
[3] Border Med Oncol, Wodonga, Australia
[4] Royal Melbourne Hosp, Melbourne, Vic, Australia
[5] Geelong Hosp, Geelong, Vic, Australia
[6] Box Hill Hosp, Box Hill, Australia
[7] Monash Med Ctr, Clayton, Vic 3168, Australia
[8] Celgene Corp, Wayne, NJ 07059 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1559
引用
收藏
页码：401A / 402A
页数：2
相关论文
共 50 条
  • [41] Phase II trial of SCIO-469 as monotherapy (M) or in combination with bortezornib (MB) in relapsed refractory multiple myeloma (MM).
    Siegel, David S.
    Krishnan, A.
    Lonial, S.
    Chatta, G.
    Alsina, M.
    Jagannath, S.
    Richardson, P.
    Hohl, R. J.
    Lust, J. A.
    Bensinger, W.
    Carrum, G.
    Moreb, J.
    Simic, A.
    Barlogie, B.
    Maziarz, R. T.
    Anderson, K. C.
    Lin, J.
    Lowe, A.
    Vetticaden, Is.
    Zhu, J.
    BLOOD, 2006, 108 (11) : 1022A - 1022A
  • [42] Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): Preliminary results.
    Farag, S. S.
    Zhang, S.
    Miller, M.
    Buckner, M.
    Kraut, E.
    Chan, K.
    Eng, C.
    Byrd, J. C.
    Dancey, J. E.
    Grever, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 450S - 450S
  • [43] Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
    Wolf, Jeffrey L.
    Siegel, David
    Goldschmidt, Hartmut
    Hazell, Katharine
    Bourquelot, Priscille M.
    Bengoudifa, Bourras R.
    Matous, Jeffrey
    Vij, Ravi
    de Magalhaes-Silverman, Margarida
    Abonour, Rafat
    Anderson, Kenneth C.
    Lonial, Sagar
    LEUKEMIA & LYMPHOMA, 2012, 53 (09) : 1820 - 1823
  • [44] Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma
    Offidani, Massimo
    Polloni, Claudia
    Cavallo, Federica
    Liberati, Anna Marina
    Ballanti, Stelvio
    Pulini, Stefano
    Catarini, Massimo
    Alesiani, Francesco
    Corvatta, Laura
    Gentili, Silvia
    Caraffa, Patrizia
    Boccadoro, Mario
    Leoni, Pietro
    Palumbo, Antonio
    LEUKEMIA & LYMPHOMA, 2012, 53 (09) : 1722 - 1727
  • [45] A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
    von Lilienfeld-Toal, Marie
    Hahn-Ast, Corinna
    Furkert, Kerstin
    Hoffmann, Florian
    Naumann, Ralph
    Bargou, Ralf
    Cook, Gordon
    Glasmacher, Axel
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 81 (04) : 247 - 252
  • [46] ACTIVITY OF MV-NIS IN A PHASE I TRIAL FOR PATIENTS WITH RELAPSED, REFRACTORY MULTIPLE MYELOMA (MM)
    Dispenzieri, A.
    Lacy, M. Q.
    Laumann, K. M.
    LaPlant, B.
    Dingli, D.
    Gertz, M. A.
    Buadi, F.
    Lowe, V.
    O'Connor, M.
    Leung, N.
    Rajkumar, S. V.
    Kumar, S. K.
    Tong, C.
    Birgin, A.
    Peng, K. W.
    Federspiel, M. J.
    Russell, S. J.
    HAEMATOLOGICA, 2014, 99 : 111 - 111
  • [47] Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma
    Chiou, Tzeon-Jye
    Wang, Teng-Hsu
    Chao, Tsu-Yi
    Lin, Sheng-Fung
    Tang, Jih-Luh
    Chen, Tsai-Yun
    Chang, Ming-Chih
    Hsueh, Erh-Jung
    Chen, Po-Min
    CANCER INVESTIGATION, 2007, 25 (03) : 140 - 147
  • [48] PHASE-II TRIAL OF PYRAZOFURIN IN PATIENTS WITH MULTIPLE-MYELOMA REFRACTORY TO STANDARD CYTOTOXIC THERAPY
    LAKELEWIN, D
    MYERS, J
    LEE, BJ
    YOUNG, CW
    CANCER TREATMENT REPORTS, 1979, 63 (08): : 1403 - 1404
  • [49] PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB
    Mian, M.
    Pescosta, N.
    Luminari, S.
    Badiali, S.
    Marcheselli, L.
    Patriarca, F.
    Zambello, R.
    Mondello, P.
    Pascarella, A.
    Marabese, A.
    Pitini, V.
    Cortelazzo, S.
    HAEMATOLOGICA, 2014, 99 : 382 - 383
  • [50] PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB
    Mian, M.
    Pescosta, N.
    Luminari, S.
    Badiali, S.
    Marcheselli, L.
    Patriarca, F.
    Zambello, R.
    Mondello, P.
    Pascarella, A.
    Pitini, V.
    Cortelazzo, S.
    HAEMATOLOGICA, 2014, 99 : 637 - 637
12345